Business Context and Reporting Period
This Form 8-K is filed by Landec Corporation (not Lifecore Biomedical, Inc., as indicated in the metadata) on September 28, 2015. The report details a material definitive agreement and the creation of a direct financial obligation by Apio, Inc., a wholly-owned subsidiary of Landec Corporation.
Key Financial Metrics and Obligations
- Facility Type: Progress Payment Agreement for financing capital equipment purchase and installation.
- Counterparty: General Electric Capital Corporation (GE Capital).
- Total Commitment: Up to $14.7 million.
- Initial Drawdown: $1.3 million drawn on September 28, 2015.
- Interest Rate: Variable at 1-month LIBOR plus 1.75% (approximately 1.94% at the time of filing).
- Repayment Terms: Monthly interest payments only during the installation period (through April 1, 2016); principal repayment is not permitted until refinancing.
- Collateral: Secured by the purchased equipment and related purchase/installation agreements.
Material Changes and Future Obligations
The filing represents a new material financial obligation. Following the installation period ending April 1, 2016, the outstanding Progress Payment Loans are scheduled to be refinanced into a term loan under an existing Credit Agreement dated April 23, 2012, and a commitment letter dated May 15, 2015. An Amendment to the Master Security Agreement was also executed concurrently to secure these loans.
Guidance, Risks, and Management Commentary
The filing does not provide specific forward-looking guidance, management commentary on financial performance, or a discussion of general risks beyond the terms of the new agreement. The primary contingency is the requirement to refinance the outstanding principal into a term loan after the installation period concludes.
Investor Verification Checklist
- Verify the total amount of capital equipment being purchased and the timeline for installation through April 1, 2016.
- Confirm the terms of the refinancing arrangement under the April 23, 2012 Credit Agreement to understand future principal repayment obligations.
- Review the full text of the Progress Payment Agreement (Exhibit 10.1) and the Amendment to the Master Security Agreement (Exhibit 10.2) for covenants or default provisions not summarized in this report.
- Note the discrepancy between the metadata company name (Lifecore Biomedical) and the actual registrant (Landec Corporation).